Literature DB >> 23937637

Chronic granulomatous disease-haematopoietic stem cell transplantation versus conventional treatment.

Anders Åhlin1, Jakob Fugeläng, Martin de Boer, Olle Ringden, Anders Fasth, Jacek Winiarski.   

Abstract

AIM: Chronic granulomatous disease (CGD) is a rare X-linked or autosomal recessive primary immune deficiency characterized by recurrent, life-threatening bacterial and fungal infections. Mortality rates are high with conventional treatment. However, haematopoietic stem cell transplantation (HSCT) offers cure. Here, we compare the outcome of HSCT in 14 Swedish patients with CGD to that in 27 patients with CGD who were given conventional treatment.
METHODS: Forty-one patients in Sweden were diagnosed with CGD between 1990 and 2012. From 1997 to 2012, 14 patients with CGD, aged 1-35 years, underwent HSCT and received grafts either from an HLA-matched sibling donor or a matched unrelated donor.
RESULTS: Thirteen of the 14 transplanted patients are alive and well. Mean age at transplantation was 10.4 years, and the mean survival time was 7.7 years. In contrast, seven of 13 Swedish men or boys with X-linked CGD who were treated conventionally died from complications of CGD at a mean age of 19 years, while the remaining patients suffered life-threatening infections.
CONCLUSION: The outcome of the patients who underwent HSCT supports HSCT as being the preferable treatment for severe CGD. Our results advocate early HSCT for all patients with X-linked CGD, using grafts from either a matched sibling donor or a matched unrelated donor. ©2013 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Chronic granulomatous disease; Conventional treatment; Haematopoietic stem cell transplantation; Morbidity; Mortality; Prognosis

Mesh:

Year:  2013        PMID: 23937637     DOI: 10.1111/apa.12384

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  13 in total

1.  Monocyte/macrophage-specific NADPH oxidase contributes to antimicrobial host defense in X-CGD.

Authors:  Yuka Okura; Masafumi Yamada; Futoshi Kuribayashi; Ichiro Kobayashi; Tadashi Ariga
Journal:  J Clin Immunol       Date:  2015-02-10       Impact factor: 8.317

Review 2.  Molecular diagnosis of chronic granulomatous disease.

Authors:  D Roos; M de Boer
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

3.  Role of Allogeneic Hematopoietic Stem Cell Transplant for Chronic Granulomatous Disease (CGD): a Report of the United States Immunodeficiency Network.

Authors:  Jennifer R Yonkof; Ashish Gupta; Pingfu Fu; Elizabeth Garabedian; Jignesh Dalal
Journal:  J Clin Immunol       Date:  2019-05-20       Impact factor: 8.317

4.  Allogeneic Reduced-Intensity Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease: a Single-Center Prospective Trial.

Authors:  Mark Parta; Corin Kelly; Nana Kwatemaa; Narda Theobald; Diane Hilligoss; Jing Qin; Douglas B Kuhns; Christa Zerbe; Steven M Holland; Harry Malech; Elizabeth M Kang
Journal:  J Clin Immunol       Date:  2017-07-28       Impact factor: 8.317

5.  Allogeneic hematopoietic stem cell transplantation using unrelated cord blood or unmanipulated haploidentical donors is effective in pediatric chronic granulomatous disease with inflammatory complications and severe infection.

Authors:  Xiangfeng Tang; Yu Zhang; Yuanfang Jing; Wei Lu; Shixia Xu; Xiuyan Cao; Youzhang Huang; Hui Yang; Nanhai Wu
Journal:  Bone Marrow Transplant       Date:  2020-03-17       Impact factor: 5.483

6.  Curative haploidentical BMT in a murine model of X-linked chronic granulomatous disease.

Authors:  Yasuo Takeuchi; Emiko Takeuchi; Takashi Ishida; Masafumi Onodera; Hiromitsu Nakauchi; Makoto Otsu
Journal:  Int J Hematol       Date:  2015-04-29       Impact factor: 2.490

7.  A Cohort of 169 Chronic Granulomatous Disease Patients Exposed to BCG Vaccination: a Retrospective Study from a Single Center in Shanghai, China (2004-2017).

Authors:  Qinhua Zhou; Xiaoying Hui; Wenjing Ying; Jia Hou; Wenjie Wang; Danru Liu; Ying Wang; Yeheng Yu; Jingyi Wang; Jinqiao Sun; Qian Zhang; Xiaochuan Wang
Journal:  J Clin Immunol       Date:  2018-03-20       Impact factor: 8.317

Review 8.  A fludarabine and melphalan reduced-intensity conditioning regimen for HSCT in fifteen chronic granulomatous disease patients and a literature review.

Authors:  Mohammad Vaezi; Maryam Souri; Seyed Amin Setarehdan; Amir Ali Hamidieh; Mohammad Reza Fazlollahi; Zahra Pourpak; Mohsen Badalzadeh; Shaghayegh Tajik; Seyed Alireza Mahdaviani; Kamran Alimoghaddam; Ardeshir Ghavamzadeh
Journal:  Ann Hematol       Date:  2022-01-08       Impact factor: 3.673

9.  Clinical and molecular features of 38 children with chronic granulomatous disease in mainland china.

Authors:  Huan Xu; Wen Tian; Shu-Juan Li; Lu-Ying Zhang; Wei Liu; Yao Zhao; Zhi-Yong Zhang; Xue-Mei Tang; Mo Wang; Dao-Qi Wu; Ji-Sheng Shi; Yuan Ding; Xiao-Dong Zhao; Xi-Qiang Yang; Li-Ping Jiang
Journal:  J Clin Immunol       Date:  2014-06-19       Impact factor: 8.317

Review 10.  Chronic Granulomatous Disease: a Comprehensive Review.

Authors:  Hsin-Hui Yu; Yao-Hsu Yang; Bor-Luen Chiang
Journal:  Clin Rev Allergy Immunol       Date:  2021-10       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.